PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Parkinson Disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
80 kilobases overlapping the 5' regulatory region shared by the Parkinson's disease gene PARK2 and the co-regulated gene PACRG.
|
14737177 |
2004 |
Parkinson Disease
|
0.030 |
Biomarker
|
disease |
LHGDN |
A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death.
|
14532270 |
2003 |
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal methylation of the common promoter of PARK2 and PACRG was observed in 26% of patients with acute lymphoblastic leukemia and 20% of patients with chronic myelogenous leukemia (CML) in lymphoid blast crisis, but not in ovarian, breast, lung, neuroblastoma, astrocytoma or colon cancer cells.
|
16287063 |
2006 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal methylation of the common promoter of PARK2 and PACRG was observed in 26% of patients with acute lymphoblastic leukemia and 20% of patients with chronic myelogenous leukemia (CML) in lymphoid blast crisis, but not in ovarian, breast, lung, neuroblastoma, astrocytoma or colon cancer cells.
|
16287063 |
2006 |
Myeloid Leukemia, Chronic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Abnormal methylation of the common promoter of PARK2 and PACRG was observed in 26% of patients with acute lymphoblastic leukemia and 20% of patients with chronic myelogenous leukemia (CML) in lymphoid blast crisis, but not in ovarian, breast, lung, neuroblastoma, astrocytoma or colon cancer cells.
|
16287063 |
2006 |
Blast Phase
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Abnormal methylation of the common promoter of PARK2 and PACRG was observed in 26% of patients with acute lymphoblastic leukemia and 20% of patients with chronic myelogenous leukemia (CML) in lymphoid blast crisis, but not in ovarian, breast, lung, neuroblastoma, astrocytoma or colon cancer cells.
|
16287063 |
2006 |
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal methylation of the common promoter of PARK2 and PACRG was observed in 26% of patients with acute lymphoblastic leukemia and 20% of patients with chronic myelogenous leukemia (CML) in lymphoid blast crisis, but not in ovarian, breast, lung, neuroblastoma, astrocytoma or colon cancer cells.
|
16287063 |
2006 |
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal methylation of the common promoter of PARK2 and PACRG was observed in 26% of patients with acute lymphoblastic leukemia and 20% of patients with chronic myelogenous leukemia (CML) in lymphoid blast crisis, but not in ovarian, breast, lung, neuroblastoma, astrocytoma or colon cancer cells.
|
16287063 |
2006 |
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Abnormal methylation of the common promoter of PARK2 and PACRG was observed in 26% of patients with acute lymphoblastic leukemia and 20% of patients with chronic myelogenous leukemia (CML) in lymphoid blast crisis, but not in ovarian, breast, lung, neuroblastoma, astrocytoma or colon cancer cells.
|
16287063 |
2006 |
Leprosy
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Although within the PARK2/PACRG gene cluster the PARK2_e01(-2599) allele T was most strongly associated with leprosy (OR approximately 3-5), the association with typhoid is much less strong.
|
16734611 |
2006 |
Typhoid Fever
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Although within the PARK2/PACRG gene cluster the PARK2_e01(-2599) allele T was most strongly associated with leprosy (OR approximately 3-5), the association with typhoid is much less strong.
|
16734611 |
2006 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
As assessed by quantitative polymerase chain reaction, PARK2 and PACRG were down-regulated in 57% and 100%, respectively, and CSF1R was up-regulated in 69% of the cc-RCC cases (concordance with SNP array data in 57%, 33%, and 38%).
|
18592004 |
2008 |
Parkinsonian Disorders
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
Deletion of the parkin and PACRG gene promoter in early-onset parkinsonism.
|
17068781 |
2007 |
Leprosy
|
0.070 |
Biomarker
|
disease |
BEFREE |
Here, we conducted high-density association mapping of PARK2/PACRG SNPs with leprosy and identified 69 SNPs significantly associated with leprosy in 198 single-case Vietnamese leprosy families.
|
23052943 |
2013 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
In conclusion, our results demonstrate for the first time that the candidate tumor suppressor genes PARK2 and PACRG are epigenetically regulated in human leukemia, suggesting that abnormal methylation and regulation of PARK2 and PACRG may play a role in the pathogenesis and development of this hematological neoplasm.
|
16287063 |
2006 |
leukemia
|
0.010 |
GeneticVariation
|
disease |
LHGDN |
In conclusion, our results demonstrate for the first time that the candidate tumor suppressor genes PARK2 and PACRG are epigenetically regulated in human leukemia, suggesting that abnormal methylation and regulation of PARK2 and PACRG may play a role in the pathogenesis and development of this hematological neoplasm.
|
16287063 |
2006 |
Hematologic Neoplasms
|
0.010 |
PosttranslationalModification
|
group |
BEFREE |
In conclusion, our results demonstrate for the first time that the candidate tumor suppressor genes PARK2 and PACRG are epigenetically regulated in human leukemia, suggesting that abnormal methylation and regulation of PARK2 and PACRG may play a role in the pathogenesis and development of this hematological neoplasm.
|
16287063 |
2006 |
Hematologic Neoplasms
|
0.010 |
PosttranslationalModification
|
group |
LHGDN |
In conclusion, our results demonstrate for the first time that the candidate tumor suppressor genes PARK2 and PACRG are epigenetically regulated in human leukemia, suggesting that abnormal methylation and regulation of PARK2 and PACRG may play a role in the pathogenesis and development of this hematological neoplasm.
|
16287063 |
2006 |
Leprosy
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
Mapping of the PARK2 and PACRG gene regulatory region with 96 SNPs, with a resolution of 1 SNP per 1 Kb for PARK2 gene regulatory region in a North Indian population, showed an involvement of 11 SNPs in determining the susceptibility towards leprosy.
|
23861666 |
2013 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome.
|
23125027 |
2013 |
Paratyphoid Fever
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
PARK2/PACRG polymorphisms and susceptibility to typhoid and paratyphoid fever.
|
16734611 |
2006 |
Parkinson Disease
|
0.030 |
Biomarker
|
disease |
LHGDN |
Parkin Co-Regulated Gene (PACRG) is regulated by the ubiquitin-proteasomal system and is present in the pathological features of Parkinsonian diseases.
|
17590346 |
2007 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Patients without PACRG mRNA expression in the tumor had a shorter disease-free survival and OS than those with tumors expressing PACRG.
|
23125027 |
2013 |
Leprosy
|
0.070 |
GeneticVariation
|
disease |
BEFREE |
The noninvolvement of major risk SNPs in the regulatory region of PARK2 and PACRG locus with leprosy susceptibility in Indian population highlights the differential effect of these SNPs in regulating genetic susceptibility to leprosy in different populations.
|
16391553 |
2006 |